In its most recent 13F filing for the third quarter, Ascent Group LLC increased its holding in Eli Lilly and Company by 3.3%, acquiring an additional 575 shares to reach a total position of 17,821 shares valued at approximately $13.6 million. Major funds made notable moves as well: Vanguard Group added 1.5% to its 80.4 million-share stake, Laurel Wealth Advisors expanded holdings by 78,621.2% to 11.6 million shares, Norges Bank established a new position worth nearly $8.8 billion, Jennison Associates boosted its stake by 4.3% to 5.4 million shares and AllianceBernstein lifted its position by 7.9% to 5.4 million shares. Overall, institutional and hedge-fund ownership stands at 82.53% of outstanding shares, underscoring continued confidence from large investors in Eli Lilly’s growth trajectory.

Eli Lilly reported third-quarter earnings per share of $7.02, surpassing consensus by $0.60, on revenues of $17.6 billion versus expectations of $16.09 billion. Year-over-year revenues jumped 53.9%, while net margin reached 30.99% and return on equity hit 109.52%. The company’s robust performance reflects accelerating demand for its flagship therapies. Management set full-year 2025 earnings guidance in the range of $23.00 to $23.70 per share, with consensus analyst estimates centered at $23.48, signaling sustained momentum through the coming fiscal year.

Eli Lilly declared a quarterly dividend of $1.73 per share, up from $1.50, with an ex-dividend date of February 13, 2026, and a payable date of March 10, 2026. On an annualized basis, this raises the dividend to $6.92, representing a yield of approximately 0.6%. The company’s dividend payout ratio stands at 29.35%, reflecting a balanced approach to returning capital to shareholders while retaining ample resources for reinvestment in research and development.

Wall Street analysts maintain a constructive outlook on Eli Lilly. Four firms rate the shares as Strong Buy, seventeen as Buy and five as Hold, culminating in a consensus 'Moderate Buy' recommendation. Price targets have been raised by several brokerages, including Wells Fargo to $1,200 and Truist to $1,182, with an average target near $1,155.36. Eli Lilly’s valuation metrics include a market capitalization of $1.02 trillion, a price-to-earnings ratio of 52.6, a PEG ratio of 1.09 and a beta of 0.37, indicating premium valuation in line with its leadership in high-growth therapeutic areas.